Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.63 |
| ▸ | NPY5R | Q15761 | 12/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | NPY2R | P49146 | 2/20 | 0.45 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.42 |
| ▸ | ACER2 | Q5QJU3 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021811 | 1.00 | GAA (0.63) | GAANPY5RALDH1A1KDM4EAOC3 | |
| SCHEMBL2021812 | 1.00 | GAA (0.63) | GAANPY5RALDH1A1KDM4EAOC3 | |
| SCHEMBL1567582 | 1.00 | GAA (0.63) | GAANPY5RALDH1A1KDM4EAOC3 | |
| SCHEMBL1567028 | 1.00 | GAA (0.63) | GAANPY5RALDH1A1KDM4EAOC3 | |
| SCHEMBL1567030 | 1.00 | GAA (0.63) | GAANPY5RALDH1A1KDM4EAOC3 | |
| SCHEMBL8730273 | 0.87 | GAA (0.65) | GAANPY5RALDH1A1KDM4EAOC3 | |
| SCHEMBL13569351 | 0.86 | GAA (0.63) | GAANPY5RALDH1A1KDM4EAOC3 | |
| SCHEMBL13570111 | 0.86 | GAA (0.63) | GAANPY5RALDH1A1KDM4EAOC3 | |
| SCHEMBL30855599 | 0.86 | GAA (0.63) | GAANPY5RALDH1A1KDM4EAOC3 | |
| SCHEMBL13328801 | 0.86 | GAA (0.63) | GAANPY5RALDH1A1KDM4EAOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | VITAE PHARMACEUTICALS, INC. | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160300-A1 | Renin Inhibitors and Methods of Use Thereof | REN, ACE, AGTR1 | GAA 157/4885NPY5R 624/4885ALDH1A1 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.